Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284687 | 0.91 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17955668 | 0.89 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28572600 | 0.88 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10146774 | 0.88 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1664013 | 0.83 | CA12 (0.75) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7929919 | 0.82 | CA1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1278720 | 0.82 | NPC1 (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL869061 | 0.82 | ESR1 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28692452 | 0.82 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2810136 | 0.82 | NPC1 (0.68) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114977-A1 | S1PR4 RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | TIAKI THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| CN-108034395-B | LED lens fixing UV glue and preparation method and application thereof | 广州惠利电子材料有限公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-3083554-B1 | DIMETHYLBENZOIC ACID COMPOUNDS | LILLY CO ELI (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10077270-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-18 | — | — | US | disclosed |
| US-10072015-B2 | HIV inhibiting bicyclic pyrimidine derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2018-09-11 | — | — | US | disclosed |
| US-10005721-B2 | Dimethylbenzoic acid compounds | ELI LILLY AND COMPANY (US) | 2018-06-26 | — | — | US | disclosed |
| US-9926276-B2 | Substituted benzamides with activity towards EP4 receptors | DRACONIS PHARMA, S.L. (ES) | 2018-03-27 | — | — | US | disclosed |
| US-20180016281-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-18 | — | — | US | disclosed |
| US-20180016281-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-18 | — | — | US | disclosed |
| EP-0661350-B1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON CATALYTIC CHEM IND (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-0632038-B1 | METHOTREXATE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-5968688-A | RESINS AND DYES FOR COLOR FILTERS | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5817843-A | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| CN-1039907-C | Methotrexate derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-09-23 | — | — | CN | disclosed |
| EP-0833203-A1 | Color filter grade photosensitive resin coloring composition, and color filter using the same | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
| US-5608091-A | SHEETS FOR HEAT EXCHANGING AND OPTICAL RECORDING MATERIAL | NIPPON SHOKUBAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0661350-A1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0632038-A1 | METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-01-04 | — | — | EP | disclosed |
| CN-1077956-A | METHOTREXATE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1993-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072015-B2 | HIV inhibiting bicyclic pyrimidine derivatives | ZC3HAV1, CCR6, ZC3HAV1L | CA12 4782/4885CA1 4496/4885CA2 4509/4885 |
| US-20180016281-A1 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES | COX6C, ZC3HAV1L, CCR6 | CA12 4775/4885CA1 4538/4885CA2 4369/4885 |
| US-10077270-B2 | HIV inhibiting bicyclic pyrimidine derivatives | ZC3HAV1, CCR6, COX6C | CA12 4766/4885CA1 4501/4885CA2 4549/4885 |
| US-10005721-B2 | Dimethylbenzoic acid compounds | PTGER4, EDNRB, EPB41 | CA12 2690/4885CA1 2400/4885CA2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.